agilon health, inc. (AGL) stock plummeted 16.25% in the after-hours trading session on Tuesday, following the company's disappointing fourth quarter 2024 earnings results and weak guidance for the upcoming fiscal year 2025.
While the healthcare services company reported revenue of $1.52 billion for Q4 2024, in line with expectations, its earnings metrics fell short. agilon health reported an adjusted loss of $0.26 per share, wider than analysts' estimates of a $0.23 per share loss. More concerningly, the company's adjusted EBITDA of -$83.97 million significantly lagged expectations of -$69.92 million.
Perhaps more worrisome for investors was agilon health's outlook for fiscal 2025. The company provided revenue growth guidance of just -2.2% year-over-year at the midpoint, a sharp deceleration from the 40.7% growth achieved in fiscal 2024. agilon health's projected 2025 EBITDA guidance of -$75 million also fell short of analyst expectations, highlighting continued profitability challenges amid what management termed a "challenging Medicare Advantage environment."
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。